Literature DB >> 6473095

Heparin-like molecules as regulators of atherogenesis.

R D Rosenberg, L M Fritze, J J Castellot, M J Karnovsky.   

Abstract

Bovine aortic endothelial cells release a heparin-like substance in the presence of 0.4% fetal calf serum. This substance inhibited the growth of smooth muscle cells in vitro by about 70%. Substitution of platelet-poor plasma for serum resulted in minimal liberation of inhibitory activity from the cells unless at least 10-fold higher concentrations of platelet-poor plasma were utilized. This suggested that a platelet product was involved in the release process. Therefore, we examined the ability of the platelet heparitinase recently isolated in our laboratory to release heparin-like species from cultured endothelial cells. Our results show that when endothelial cells were exposed to serum-free medium containing 1 ng/ml of the purified platelet endoglycosidase, at least as much inhibitory activity was released as was obtained with 0.4% serum. Dose response experiments indicated that only 10 pg/ml of the enzyme were necessary to liberate 50% of the inhibitory activity from endothelial cells. The heparin-like nature of the inhibitory substance was demonstrated by its sensitivity of Flavobacterium heparinase. Utilizing appropriate controls, the release of heparin-like material by the endoglycosidase was shown to be enzyme-specific and was not due to artifacts of experimental manipulations. In addition, this enzyme did not convert prereleased material to an active component, but directly liberated the active heparin-like species from endothelial cells. A simple model describing the possible role of heparin-like components and the endoglycosidase in the normal and injured wall will be presented.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6473095

Source DB:  PubMed          Journal:  Nouv Rev Fr Hematol


  2 in total

Review 1.  Angiostatic steroids. Method of discovery and mechanism of action.

Authors:  J Folkman; D E Ingber
Journal:  Ann Surg       Date:  1987-09       Impact factor: 12.969

2.  Mesoglycan attenuates VSMC proliferation through activation of AMP-activated protein kinase and mTOR.

Authors:  Kyung Young Lee; Dong Hyup Lee; Hyoung Chul Choi
Journal:  Clin Hypertens       Date:  2016-01-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.